DE60039415D1 - Reovirus zur behandlung von zellulären proliferativen erkrankungen - Google Patents

Reovirus zur behandlung von zellulären proliferativen erkrankungen

Info

Publication number
DE60039415D1
DE60039415D1 DE60039415T DE60039415T DE60039415D1 DE 60039415 D1 DE60039415 D1 DE 60039415D1 DE 60039415 T DE60039415 T DE 60039415T DE 60039415 T DE60039415 T DE 60039415T DE 60039415 D1 DE60039415 D1 DE 60039415D1
Authority
DE
Germany
Prior art keywords
reovirus
treatment
proliferative diseases
cellular proliferative
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039415T
Other languages
English (en)
Inventor
Patrick W Lee
James Strong
Matthew C Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DE60039415D1 publication Critical patent/DE60039415D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
DE60039415T 1999-02-24 2000-02-18 Reovirus zur behandlung von zellulären proliferativen erkrankungen Expired - Lifetime DE60039415D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/256,824 US6136307A (en) 1997-08-13 1999-02-24 Reovirus for the treatment of cellular proliferative disorders
PCT/CA2000/000178 WO2000050051A2 (en) 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
DE60039415D1 true DE60039415D1 (de) 2008-08-21

Family

ID=22973731

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039415T Expired - Lifetime DE60039415D1 (de) 1999-02-24 2000-02-18 Reovirus zur behandlung von zellulären proliferativen erkrankungen

Country Status (17)

Country Link
US (8) US6136307A (de)
EP (2) EP1156813B1 (de)
JP (1) JP2002537344A (de)
AR (1) AR022734A1 (de)
AT (1) ATE400283T1 (de)
AU (1) AU776401C (de)
CA (1) CA2360833C (de)
DE (1) DE60039415D1 (de)
DK (1) DK1156813T3 (de)
ES (1) ES2308971T3 (de)
HK (1) HK1039752B (de)
IL (3) IL144043A0 (de)
MX (1) MXPA01008457A (de)
NZ (2) NZ529362A (de)
PT (1) PT1156813E (de)
TW (1) TWI290467B (de)
WO (1) WO2000050051A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
WO2001035970A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) * 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AU7926401A (en) * 2000-06-26 2002-01-08 Pro Virus Inc Purging of cells using viruses
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
WO2002039117A1 (en) 2000-11-09 2002-05-16 Oncolytics Biotech, Inc. Methods for the treatment of cellular proliferative disorders
WO2002040042A2 (en) * 2000-11-20 2002-05-23 Oncolytics Biotech, Inc. Method for optimally delivering virus to a solid tumor mass
CA2430495A1 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003011230A2 (en) * 2001-08-03 2003-02-13 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
EP1944035A1 (de) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Verfahren zur Schmerzlinderung durch onkolytische Viren
MXPA04011007A (es) * 2002-05-09 2005-02-14 Oncolytics Biotech Inc Metodo para reducir el dolor usando virus oncoliticos.
ATE554781T1 (de) * 2002-05-10 2012-05-15 Oncolytics Biotech Inc Onkolytische viren zur sensibilisierung neoplastischer zellen für die strahlentherapie
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
MXPA05011462A (es) * 2003-04-25 2005-12-15 Wellstat Biologics Corp Tratamiento de carcinomas hepatocelulares utilizando virus terapeuticos.
US7588767B2 (en) 2003-06-18 2009-09-15 Genelux Corporation Microorganisms for therapy
US20050019308A1 (en) * 2003-07-07 2005-01-27 Oncolytics Biotech Inc. Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2617600A1 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US7828978B2 (en) * 2006-01-11 2010-11-09 Doug Geier Simultaneous synthesis and purification of a fatty acid monoester biodiesel fuel
CA2640286C (en) * 2006-02-13 2018-01-02 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
CA2693623A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
CA2699805A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
EP2300023A2 (de) * 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
CN102065873A (zh) * 2008-05-27 2011-05-18 昂科利蒂克斯生物科技公司 在溶瘤呼肠孤病毒治疗中消除促炎细胞因子的产生
JP2011520993A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク，インコーポレーテッド 間質圧力の調節並びに腫瘍崩壊性ウイルスの送達及び分布
EP2697368B1 (de) 2011-04-15 2019-06-05 Genelux Corporation Klonale stämme von abgeschwächten vaccinia-viren und verwendungsverfahren davon
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
EP3068411B1 (de) 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Onkolytische viren und wirksamere krebsbehandlungsschemata
SG11201703326SA (en) 2014-10-24 2017-05-30 Aladar Szalay Combination immunotherapy approach for treatment of cancer
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
CN113347980A (zh) 2019-01-18 2021-09-03 天主教鲁汶大学 病毒组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
PT70556A (en) 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH04503306A (ja) * 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
AU5275290A (en) * 1989-04-11 1990-11-05 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
ES2134346T3 (es) * 1993-02-16 1999-10-01 Onyx Pharma Inc Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
US5525342A (en) 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5614403A (en) * 1994-06-01 1997-03-25 Baylor College Of Medicine In vitro replication system capable of rescuing cloned and manipulated rotavirus genes
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1998008541A1 (en) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
EP1905304A3 (de) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
ATE554781T1 (de) * 2002-05-10 2012-05-15 Oncolytics Biotech Inc Onkolytische viren zur sensibilisierung neoplastischer zellen für die strahlentherapie
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
SG149870A1 (en) * 2005-08-31 2009-02-27 Oncolytics Biotech Inc Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス

Also Published As

Publication number Publication date
US20120141426A1 (en) 2012-06-07
HK1039752A1 (en) 2002-05-10
US20110014155A1 (en) 2011-01-20
US20030003080A1 (en) 2003-01-02
CA2360833C (en) 2008-05-13
PT1156813E (pt) 2008-09-02
EP1156813A2 (de) 2001-11-28
HK1039752B (zh) 2008-11-21
AU776401B2 (en) 2004-09-09
NZ529362A (en) 2005-03-24
ATE400283T1 (de) 2008-07-15
EP1156813B1 (de) 2008-07-09
CA2360833A1 (en) 2000-08-31
US8709443B2 (en) 2014-04-29
US20090117082A1 (en) 2009-05-07
NZ512661A (en) 2004-04-30
US6136307A (en) 2000-10-24
US7374752B2 (en) 2008-05-20
US6811775B2 (en) 2004-11-02
TWI290467B (en) 2007-12-01
JP2002537344A (ja) 2002-11-05
IL144043A0 (en) 2002-04-21
WO2000050051A2 (en) 2000-08-31
WO2000050051A3 (en) 2000-12-28
AR022734A1 (es) 2002-09-04
US6455038B1 (en) 2002-09-24
US8071087B2 (en) 2011-12-06
DK1156813T3 (da) 2008-10-13
US8066985B2 (en) 2011-11-29
AU2788100A (en) 2000-09-14
IL144043A (en) 2009-12-24
IL197903A (en) 2014-02-27
MXPA01008457A (es) 2002-06-21
AU776401C (en) 2005-04-28
ES2308971T3 (es) 2008-12-16
US20080026048A1 (en) 2008-01-31
US20050063954A1 (en) 2005-03-24
EP1949905A1 (de) 2008-07-30

Similar Documents

Publication Publication Date Title
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60022826D1 (de) Absorbierender Wegwerfartikel zur Behandlung von Fäkalien
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE50009813D1 (de) Kombinationpräparat zur behandlung von sexueller dysfunktion
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition